Second Affiliated Hospital of Xinjiang Medical University

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

Retrieved on: 
Monday, August 7, 2023
Second Affiliated Hospital of Xinjiang Medical University, Visual analogue scale, Migraine, Depression, Prevalence, HHS, PSQI, MSQ, Clinical trial, World Health Organization, DSM-IV codes, Department of Neurology, Xuanwu hospital, Zhengzhou University, VAS, HAMA, Trial of the century, MDE, Pain, MDD, Patient, Grammatical mood, Pittsburgh Sleep Quality Index, Research, The Rheumatoid Arthritis Quality of Life Questionnaire, WHO, International Journal of Research in Marketing, Pharmaceutical industry, Brain

As part of the clinical study, 40 migraine patients (without migraine aura) were treated at the Vertigo Center.

Key Points: 
  • As part of the clinical study, 40 migraine patients (without migraine aura) were treated at the Vertigo Center.
  • The migraine study follows the Company’s recent clinical study in depression, which demonstrated statistically significant improvements among patients.
  • Mark White, CEO of Nexalin Technology, stated, "Research and Markets estimates the migraine and depression markets at roughly $3.9 billion and $11.2 billion, respectively.
  • We look forward to conducting additional clinical trials in new indications – many of which will be fully funded by Wider, our new JV partner.”

HTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19

Retrieved on: 
Thursday, April 6, 2023
HTG, AACR, Second Affiliated Hospital of Xinjiang Medical University, UT, GEP, HTP, Merck Group, Research, RNA, Gene expression profiling, Science, MD Anderson Cancer Center, Transcriptome, Xi'an Jiaotong University, University, Providence Saint Joseph Medical Center, Drug discovery, SVP, Pharmaceutical industry

TUCSON, Ariz., April 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced there will be at least four scientific posters featuring its proprietary HTG EdgeSeq™ technology presented at the American Association for Cancer Research Annual Meeting (AACR) April 16-19 in Orlando, Florida.

Key Points: 
  • TUCSON, Ariz., April 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced there will be at least four scientific posters featuring its proprietary HTG EdgeSeq™ technology presented at the American Association for Cancer Research Annual Meeting (AACR) April 16-19 in Orlando, Florida.
  • Global leaders in cancer research, including The University of Texas MD Anderson Cancer Center, Providence Saint John’s Health Center and Merck KGaA, will be sharing research conducted utilizing the HTG EdgeSeq platform gene expression profiling (GEP).
  • The science being presented at AACR highlights the broad spectrum of applications utilizing HTG’s ultra-efficient RNA profiling platform and the Company’s capabilities from biomarker discovery and genomic signatures to drug discovery.
  • “We are proud to partner with such innovative and world-renowned research centers and biopharma partners who use our novel transcriptomic technology to take their research and science to new heights.”

5G In Healthcare Market Report 2022: Demand for a Real-Time Network With Faster Internet Access Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022
Health, Other Health, Zhejiang University School of Medicine, Adoption, Health, COVID-19, Machine learning, Telehealth, Hardwar, Second Affiliated Hospital of Xinjiang Medical University, Growth, Component, Government, Patient, USD, Diagnosis, Artificial intelligence, Ecosystem, Remote patient monitoring, Insurance, Hospital, VR, IOT, CAGR, Medical device, Renewable energy, Pharmaceutical industry, Mobile phone, Health insurance, Healthcare

The global 5G in healthcare market size is expected to reach USD 454.7 billion by 2030, based on a new report, expanding at a CAGR of 34.5% from 2022 to 2030.

Key Points: 
  • The global 5G in healthcare market size is expected to reach USD 454.7 billion by 2030, based on a new report, expanding at a CAGR of 34.5% from 2022 to 2030.
  • The IoT ecosystem is developing and is expected to enable networks to connect billions of devices.
  • The demand for a real-time network with faster internet access and greater bandwidth has been driven by the development of modern technologies such as artificial intelligence, wired, and wireless communications, and machine learning.
  • For instance, the government of India launched a special incentive scheme to support 75 startups in telemedicine and digital health in 2021
    Chapter 5 5G in Healthcare Market: Component Analysis
    Chapter 6 5G in Healthcare Market: Application Analysis
    Chapter 7 5G in Healthcare Market: End-use Analysis
    Chapter 8 5G in Healthcare Market: Regional Analysis

5G In Healthcare Market to be Worth $454.7 Billion By 2030: Grand View Research, Inc.

Retrieved on: 
Wednesday, August 24, 2022
Zhejiang University School of Medicine, Machine learning, COVID-19, VR, Insight, Telehealth, Artificial intelligence, Government, SAN, Insurance, Hardwar, USD, Health, IOT, Diagnosis, Second Affiliated Hospital of Xinjiang Medical University, Hospital, Component, Remote patient monitoring, CAGR, Revenue, Ecosystem, Growth, Adoption, Patient, Mobile phone, Medical device, Healthcare, Coal

Moreover, the market is driven by the increasing demand for wearable medical devices incorporated with 5G technology for real-time remote patient monitoring and the rising acceptance of robotic surgery and telehealth.

Key Points: 
  • Moreover, the market is driven by the increasing demand for wearable medical devices incorporated with 5G technology for real-time remote patient monitoring and the rising acceptance of robotic surgery and telehealth.
  • The services component segment is anticipated to expand at the fastest CAGR of 35.7% from 2022 to 2030.
  • The growth is attributed to the need for improved mobile broadband and greater frequencies offered by 5G services.
  • Grand View Research has segmented the global 5G in healthcare market based on component, application, end-use, and region:
    5G In HealthcareMarket - Component Outlook (Revenue, USD Billion, 2017 - 2030)
    5G In HealthcareMarket - Application Outlook (Revenue, USD Billion, 2017 - 2030)

5G In Healthcare Market to be Worth $454.7 Billion By 2030: Grand View Research, Inc.

Retrieved on: 
Wednesday, August 24, 2022
Zhejiang University School of Medicine, Machine learning, COVID-19, VR, Insight, Telehealth, Artificial intelligence, Government, SAN, Insurance, Hardwar, USD, Health, IOT, Diagnosis, Second Affiliated Hospital of Xinjiang Medical University, Hospital, Component, Remote patient monitoring, CAGR, Revenue, Ecosystem, Growth, Adoption, Patient, Mobile phone, Medical device, Healthcare, Coal

Moreover, the market is driven by the increasing demand for wearable medical devices incorporated with 5G technology for real-time remote patient monitoring and the rising acceptance of robotic surgery and telehealth.

Key Points: 
  • Moreover, the market is driven by the increasing demand for wearable medical devices incorporated with 5G technology for real-time remote patient monitoring and the rising acceptance of robotic surgery and telehealth.
  • The services component segment is anticipated to expand at the fastest CAGR of 35.7% from 2022 to 2030.
  • The growth is attributed to the need for improved mobile broadband and greater frequencies offered by 5G services.
  • Grand View Research has segmented the global 5G in healthcare market based on component, application, end-use, and region:
    5G In HealthcareMarket - Component Outlook (Revenue, USD Billion, 2017 - 2030)
    5G In HealthcareMarket - Application Outlook (Revenue, USD Billion, 2017 - 2030)

EuroEyes signs tri-party agreement of mutual cooperation with leading medical universities in the PRC and Germany

Retrieved on: 
Friday, July 29, 2022
Group, Surgeon, Heidelberg University, Moran Eye Center, University, Education, AMC, Heidelberg University Eye Clinic, Doctor of Philosophy, Student, CEO, Entrepreneurship, Research, Zhejiang University School of Medicine, COVID-19, Second Affiliated Hospital of Xinjiang Medical University, Achievement, COO, Science, Patient, Medical school, International relations, Growth, JIN, HKEX, Chair, Hospital, Management, Pharmaceutical industry, Medicine, Ophthalmology, PRC, 2018 EuroEyes Cyclassics

HONG KONG, July 29, 2022 /PRNewswire/ -- EuroEyes International Eye Clinic Limited ("EuroEyes" or the "Company", together with its subsidiaries, the "Group", HKEX: 1846) announced on 27 July that it has signed a tri-party agreement of mutual cooperation ("AMC") with the Eye Center of Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang University Eye Hospital and The David J. Apple International Laboratory for Ocular Pathology & International Vision Correction Research Centre (IVCRC), University Eye Clinic of the Ruprecht-Karls-University of Heidelberg. The AMC aims to establish closer cooperation between eye care professionals in the PRC and Germany that could foster new innovations in ophthalmology, and enhance the skills of surgeons at EuroEyes and in the two countries who could contribute to the continued development in eye care.

Key Points: 
  • Jrn S. Jrgensen, Founder, Chairman and CEO of EuroEyes and Prof. Dr. Michael Knorz, EuroEyes Senior Vice President and Professor of Ophthalmology at University of Heidelberg, Medical Faculty Mannheim.
  • Ophthalmologists from EuroEyes, Heidelberg University Eye Clinicand Second Affiliated Hospital of Zhejiang University School of Medicine will have the opportunity to pursue a 3 to 6 months fellowship in the PRC and Germany.
  • We believe the collaboration will help EuroEyes identify talented students and surgeons in the PRC, offering them with local understandings, postgraduate experiences and knowledge exchanges in Germany.
  • Meanwhile, surgeons in Germany will be given opportunities to possess a wealth of on-the-ground experience in the PRC.

Tianlong launched a campaign to care for SMA children

Retrieved on: 
Thursday, July 14, 2022
Technology, Disease, Lists of diseases, SMN1, SMA, Solution, Child, Human, Patient, Love, Social responsibility, COVID-19, Second Affiliated Hospital of Xinjiang Medical University, Xi'an Jiaotong University, Spine, PCR, Muscle, Parent, Vaccine, Toy

XI'AN China, July 14, 2022 /PRNewswire/ -- Tianlong has launched a campaign together with the Spinal muscular atrophy (SMA) care center in China (a non-profit organization for SMA), and The Second Affiliated Hospital of Xi'an Jiaotong University to care for children with SMA in May 2022.

Key Points: 
  • XI'AN China, July 14, 2022 /PRNewswire/ -- Tianlong has launched a campaign together with the Spinal muscular atrophy (SMA) care center in China (a non-profit organization for SMA), and The Second Affiliated Hospital of Xi'an Jiaotong University to care for children with SMA in May 2022.
  • Tianlong always bears social responsibility and strives for making more people know about the disease and helping with early detection.
  • During the campaign, we invited many families in Xi'an, China to join us to accompany SMA children one day.
  • As a leading molecular diagnosis products manufacturer in China, Tianlong has PCR reagents covering 200 kinds of disease detection, including SMA detection.

Tianlong launched a campaign to care for SMA children

Retrieved on: 
Thursday, July 14, 2022
Technology, Disease, Lists of diseases, SMN1, SMA, Solution, Child, Human, Patient, Love, Social responsibility, COVID-19, Second Affiliated Hospital of Xinjiang Medical University, Xi'an Jiaotong University, Spine, PCR, Muscle, Parent, Vaccine, Toy

XI'AN China, July 14, 2022 /PRNewswire/ -- Tianlong has launched a campaign together with the Spinal muscular atrophy (SMA) care center in China (a non-profit organization for SMA), and The Second Affiliated Hospital of Xi'an Jiaotong University to care for children with SMA in May 2022.

Key Points: 
  • XI'AN China, July 14, 2022 /PRNewswire/ -- Tianlong has launched a campaign together with the Spinal muscular atrophy (SMA) care center in China (a non-profit organization for SMA), and The Second Affiliated Hospital of Xi'an Jiaotong University to care for children with SMA in May 2022.
  • Tianlong always bears social responsibility and strives for making more people know about the disease and helping with early detection.
  • During the campaign, we invited many families in Xi'an, China to join us to accompany SMA children one day.
  • As a leading molecular diagnosis products manufacturer in China, Tianlong has PCR reagents covering 200 kinds of disease detection, including SMA detection.

Burning Rock Announces the Launch of China’s First Prospective Interventional Validation Study on Multi-Cancer Early Detection - the PREVENT Study

Retrieved on: 
Thursday, June 30, 2022
Diagnosis, U.S. News & World Report Best Hospitals Rankings, Science, Patient, CEO, Sichuan University, Liver, Securities Exchange Act of 1934, Research, NGS, Second Affiliated Hospital of Xinjiang Medical University, GLOBE, Cancer, Annual report, Forward-looking statement, Terminology, Hope, Compliance, Fudan University, Policy, Wuhan Union Hospital, Hospital, Technology, Intervention, Lung, Quality of life, SEC, ISBN, Incidence, Medical school, Private Securities Litigation Reform Act, NASDAQ, Pathology, Dalian Medical University, Physician, WCH, Medical imaging, Water Drops on Burning Rocks

The study is led by Dr. Weimin Li, head of the West China Hospital of Sichuan University.

Key Points: 
  • The study is led by Dr. Weimin Li, head of the West China Hospital of Sichuan University.
  • "Cancer early detection, diagnosis and treatment is the key to reducing cancer burden.
  • "The PREVENT study is at the cutting edge of cancer early detection and management.
  • Yusheng Han, CEO of Burning Rock, remarked that "Multi-cancer early detection through liquid-biopsy is a strategic focus of Burning Rock.

DGAP-News: Lisen Imprinting Diagnostics Announces a Revolutionary Early Diagnostic Method for Lung Cancer

Retrieved on: 
Monday, December 20, 2021
Medical school, Shanghai Chest Hospital, Degenerative disease, Fudan University, Cancer, Diagnosis, Lung cancer, Allele, Biomarker, Critical Care Medicine (journal), Breast, First Department, Survival, Institute, Lung, Prostate, Johns Hopkins University, CEO, Research, Gene, Neoplasm, Patient, Mortality, Paper, Respiratory Medicine, Department, R, Carcinoma, Ohio State University, Second Affiliated Hospital of Xinjiang Medical University, PA, Impact, Technology, Medical imaging, Southeast University, Lisen Imprinting Diagnostics, Inc., Imprinted Genes, LISEN IMPRINTING DIAGNOSTICS, INC., IMPRINTED GENES

WUXI, CHINA & PHILADELPHIA, PA / ACCESSWIRE / December 15, 2021 / Lisen Imprinting Diagnostics ("LisenID" or "the company") announces an innovative and ground-breaking epigenetics-based diagnostic solution for early lung cancer detection.

Key Points: 
  • WUXI, CHINA & PHILADELPHIA, PA / ACCESSWIRE / December 15, 2021 / Lisen Imprinting Diagnostics ("LisenID" or "the company") announces an innovative and ground-breaking epigenetics-based diagnostic solution for early lung cancer detection.
  • The present study particularly focused on lung cancer, which has the highest reported mortality among all cancers.
  • This method could greatly improve the diagnostic performance of preoperative cytopathology, promote the early diagnosis and treatment of lung cancer, and increase the survival of lung cancer patients.
  • During preoperative detection, the diagnostic model can accurately distinguish benign lung diseases from lung cancer demonstrating far superior diagnostic sensitivity than cytopathology, particularly for early lung cancer and small lung nodules.